Celltex is committed to sound, responsible and ethical stem cell technology and to leading the development of policy for responsible research and therapy using stem cells.
To better understand the therapeutic impact and monitor the safety of adult stem cell therapy, we are sponsoring clinical trials. The protocols, which have been subject to review and approval by an independent Institutional Review Board (IRB), mandate a comprehensive informed consent process and provide for on-going oversight for both safety and research integrity.
Celltex will release stem cells only to physicians who are investigators in the approved protocols and who have completed appropriate training in clinical research ethics.
Physicians can administer cells only to patients who have consented and meet all the inclusion/exclusion criteria in the clinical trial studies.
Consistent with our commitment to the overall advancement of regenerative medicine, Celltex plans to publish the clinical findings gained through its protocols. These data will help advance the knowledge of adult stem cell therapy for the medical community for years to come.
For information on enrolling in our clinical trials, please contact us.